ATLAS Score for Clostridium Difficile Infection

The ATLAS score is a bedside tool that estimates the severity of Clostridioides difficile infection and risk of adverse outcomes.

Age, years
< 60060-79+1≥ 80+2
Tx w/ systemic antibiotics during C. diff infection therapy (≥ 1 day duration)
No0Yes+2
Leukocyte count, cells/uL
< 16,000016,000-25,000+1> 25,000+2
Serum albumin
> 3.5 g/dL (> 35 g/L)02.6-3.5 g/dL (26-35 g/L)+1< 2.6 g/dL (< 26 g/L)+2
Serum creatinine (as a measure of renal function)
≤ 1.3 mg/dL (≤ 120 μmol/L)01.4-2.0 mg/dL (121-179 umol/L)+1≥ 2.1 mg/dL (≥ 180 umol/L)+2

Indicaciones de Uso

Used for hospitalized adults with confirmed CDI to estimate severity and risk of severe outcomes (ICU, colectomy, mortality) and to guide early treatment intensity. Most accurate among legacy bedside scores but only moderate discrimination (AUROC ~0.78) on external validation 1 [Level II evidence]. Helpful at diagnosis for risk stratification, not for predicting recurrence (poor performance vs other tools) 2 [Level II evidence].

Información y Precauciones

Predicts severe CDI using age, treatment, leukocytosis, albumin, and serum creatinine but shows only moderate discrimination and poor external validity (AUROC ~0.78; external AUC often ≤0.66) 1 [Level II evidence]; 2 [Level II evidence].
• Variables are easy to obtain but underperform across institutions and may misclassify toxin‑negative/NAAT‑positive cases.
• Should not guide treatment alone—confirm severity with clinical parameters.